Pulmonary HypertensionReserveNCT04188756
RV Systolic and Diastolic Function and Contractile Reserve Under Acute Exercise and in Response to Chronic Exercise-based Rehabilitation
A study testing Exercise in people with Pulmonary Hypertension and Right Heart Failure, run by University of Giessen at 1 site in Germany.
Trial summary
Exercise training in Pulmonary arterial hypertension in the setting of rehabilitation leads to an enormous improvement of functional state and haemodynamics. However the underlying mechanism is still unkown. Read more about this study
- Who is it for?
- Ages 18 to 75 years
- Conditions the study is for
- Pulmonary Hypertension, Right Heart Failure, Heart Failure
- What is being tested?
- Exercise
- Could I receive a placebo?
- No, everyone receives an active treatment
- How many people
- 84 participants
- Where
- 1 siteGermany
- Study dates
- 1 Jul 2022to 1 Jul 2024
- Phase
- Interventional
- Are there results?
- None posted in the registry
Key requirements
Who can take part, as listed by the sponsor. Only the study team can confirm whether you are eligible, so take this list to your doctor.
- Ages 18 to 75 years
- All sexes
- No healthy volunteers
- Adult, Older adult
Who may be able to join
- Consent form,
- men and women> 18 years <75 years
- invasively confirmed chronic PH who have received complete diagnostic evaluation by specialized physicians according to at a center for pulmonary hypertension and were adjusted for 2 months under intensive medical therapy and are stable
Who cannot join
- Pregnancy or lactation,
- Change in medication during the last 2 months,
- Patients with signs of right heart decompensation, severe walking disturbance,
- No previous invasively confirmation of PH, acute diseases, Infections, fever,
- active myocarditis, unstable angina pectoris, exercise-induced ventricular -arrhythmias, congestive heart failure, significant heart disease, pacemakers, and -hypertrophic obstructive cardiomyopathy, or a highly reduced left ventricular function
Trial locations and contacts
1 site in 1 country.
Germany1 site
University Hospital Giessen
Giessen, 35392
Khodr Tello, MD, 004964198556087, khodr.tello@innere.med.uni-giessen.de
Manuel Richter, MD, 004964198556022, manuel.richter@innere.med.uni-giessen.de
About this study
Exercise training in Pulmonary arterial hypertension in the setting of rehabilitation leads to an enormous improvement of functional state and haemodynamics. However the underlying mechanism is still unkown. It is assumed to be relied on Right ventricular contractile reserve, but this has never been proven with goldstandard PV-loop assessment.
Our aim is to evaluate the mechanism leading to the increase in functional state and to evaluate the impact of exercise (acute and chronic) on right ventricular performance
Read the detailed description
The ability of the RV to increase Ees under exercise is barely understood, and it is not known whether this is accompanied by changes in Eed. Exercise-based rehabilitation programs in PAH patients showed a marked increase in 6 Minute Walk distance and CI; the improvement was, partially higher than the improvement upon targeted PAH medication Several mechanisms may underlie such improvement, in particular a decrease in PVR, improved peripheral muscular function and improved systolic and/or diastolic RV function. To assess the latter aspect in a load-independent fashion, the investigators will perform acute exercising and exercise-based rehabilitation in PAH patients with performance of RV PV loop measurements, which has never been undertaken under this aspect in PAH patients.
Acute exercising: As "physiological response" to acute exercising, an increase in RV Ees is to be expected. However, based on clinical experience and on the surprising finding of an Ees decrease upon volume challenge in patients with low Ees/Ea values, the investigators hypothesize that orientation and extent of the Ees response to acute exercise will depend on the baseline Ees/Ea: patients with well-maintained Ees/Ea values may reveal an increase of Ees in response to acute exercise, whereas patients with RV-PA uncoupling (baseline Ees/Ea < 0.8) may show an acute heterometric adaptation with increase in volumes and decrease in Ees (negative ∆ Ees). Moreover, this study may again provide a novel "threshold of uncoupling" (Ees/Ea ratio), at which the RV response to acute exercising switches from increased to decreased contractility. The investigators will use incremental exercise tests (step or ramp protocol; handgrip protocol) with repeated hemodynamic measurements with right heart catheterization (RHC) and PV-loop catheter. The modified single beat method will be used to calculate Ees and Ea as well as Eed under exercise: the intercept on the x-axis will be predefined by Valsalva maneuver and preload reduction, and this point will be the reference for PV-loop-derived ESPVR to calculate Ees as decribed before. The study will include 42 PAH patients, who will subsequently be entered into the rehabilitation program (for power calculation see below). Similar to the volume challenge study, the hypothesis is that extent and orientation of ∆ Ees upon acute exercise are correlated with baseline Ees/Ea. Primary endpoint: ∆ Ees between baseline and maximum exercise. Secondary endpoints: time to recovery of Ees and RV-EDV after acute exercising, changes in PVR, mPAP, CI, Eed, Ea, Stroke Work, EDP, ESV, EDV and SV. Statistics: the primary endpoint will be analyzed by descriptive statistics, graphical representations with scatterplots, quantitative measures of dependence (Pearson's r or Spearman´s rho) and description of conditional distributions will be used.
Exercise-based rehabilitation - the RESERVE study: The investigators aim to conduct a single center, interventional, randomized, non-blinded, prospective study to evaluate the impact of exercise training on RV-PA- coupling. Every patient will undergo acute exercise testing during first catheterization as described above. Thereafter, patients will be randomly assigned to a control and a training group for chronic exercise in a rehabilitation program. Medication will remain unchanged during the study period. After 15 weeks, RHC and PV-loop assessment at baseline and in response to acute exercise will be repeated. During the study, patients of the control group will not receive any advice on exercise training. Rehabilitation-exercise training will consist of High Intensity Interval Training (HIIT) as described before . Retesting (baseline, response to exercise) will be performed after 15 weeks. Different examinations will be performed at the different visits. Primary endpoint will be the change in baseline Ees over the 15 weeks observation period. Secondary endpoints include the Ees response to acute exercising as well as further PV-loop, cMRI, Echo-derived and functional parameters as detailed in Table 2. Statistics: Continuous variables will be compared using repeated-measures ANOVA for differences between values at baseline and after acute and chronic exercise challenge. The comparisons of characteristics at baseline and after exercise between the two groups, as well as the comparisons of the absolute changes of variables from baseline to post-exercise between groups will be analyzed by adequate descriptive statistics.
- Conditions
- Pulmonary Hypertension, Right Heart Failure, Heart Failure, Contractility, RV-arterial Coupling
- Being tested
- Exercise
- Medical subject headings
- Hypertension, Pulmonary, Heart Failure
What participants receive
What participants receive. In a randomised study each person is assigned to one group by chance.
ExerciseOther
High intensity interval training (rehabilitation) over 15 weeks. Patients will be guided by physicians for exercise training in Pulmonary hypertension
| Study group | Role | What they receive |
|---|---|---|
| Exercise | Other | Group under exercise training for 15 weeks with High intenstiy interval training under medical control Receives: Other: Exercise |
| Control | No intervention | Group with standard care according to current guidelines |
What is being measured
The primary outcome is the main question the study is designed to answer.
Primary endpoint will be the change in baseline Ees over the 15 weeks observation period
Ees(endsystolic elastance) is a measure of coontractility
Measured: over 15 weeks
Secondary outcomes (8)
Global longitudinal strain
Cardiac MRI measures of function, expressed in %
Measured: over 15 weeks
PVR
Right Heart catheter measures of afterload, expressed in Wood Units
Measured: April 2020 until July 2022
Walking distance in 6MW
functional state, expressed in meter
Measured: over 15 weeks
TAPSE,
Echocardiography measure of function, expressed in mm
Measured: over 15 weeks
mPAP
Pressure in Right heart catheter, expressed in mmHg
Measured: over 15 weeks
Cardiac Output
Functional parameter, expressed in liter per minute
Measured: over 15 weeks
T1 mapping
Cardiac MRI parameter, expressed in ms
Measured: over 15 weeks
Fractional area change
Echocardiography measure of function, expressed in %
Measured: over 15 weeks
Timeline
From the start of the study to its completion; the mark is today. Estimated dates are the sponsor’s plan.
- First posted6 Dec 2019
- Study start1 Jul 2022 (estimated)
- Primary completion1 Feb 2023 (estimated)
- Study completion1 Jul 2024 (estimated)
Resources
- Official record on ClinicalTrials.govThe registry entry this page is built from, with its full change history.
- Other trials for Pulmonary HypertensionStudies of the same condition, open and under way.
- What the trial phases meanHow a treatment moves from first tests in people to approval.
More details
For doctors and researchers: how the study is designed, who runs it, and its registry IDs.
Study design
- Study type
- Interventional
- Phase
- Phase N/A
- Primary purpose
- Treatment
- Allocation
- Randomised
- Intervention model
- Single group
- Model description
- Patients will randomized for exercice (1:1). After 15 weeks the group without exercise will be offered to take part in an exercise training
- Masking
- None (open label)
- Enrolment
- 84 participants (estimated)
Sponsor and investigators
- Lead sponsor
- University of Giessen
- Sponsor type
- University, hospital or other
- Responsible party
- Sponsor
IDs, dates and publications
- ClinicalTrials.gov ID
- NCT04188756
- Sponsor's protocol ID
- UniGiessenReserve
- Acronym
- Reserve
- Status last verified
- Nov 2021
- First submitted
- 26 Nov 2019
- Last updated
- 9 Nov 2021
- Results posted
- No
- Data monitoring committee
- No
- FDA-regulated drug
- No
- FDA-regulated device
- No
- Individual data sharing
- No
Study at a glance
From the registry record, last updated by the sponsor on 9 Nov 2021. Recruitment status is as the sponsor reported it: confirm with the study team.
- Official title
- RV Systolic and Diastolic Function and Contractile Reserve Under Acute Exercise and in Response to Chronic Exercise-based Rehabilitation
- ClinicalTrials.gov ID
- NCT04188756
- Acronym / sponsor ID
- Reserve / UniGiessenReserve
- Conditions
- Pulmonary Hypertension, Right Heart Failure, Heart Failure, Contractility, RV-arterial Coupling
- Study type
- Interventional
- Recruitment status
- Unknown status
- Enrolment
- 84 participants (estimated)
- Lead sponsor
- University of GiessenUniversity, hospital or other
- Study start
- 1 Jul 2022 (estimated)
- Primary completion
- 1 Feb 2023 (estimated)
- Study completion
- 1 Jul 2024 (estimated)
- First posted
- 6 Dec 2019 (actual)
- Results
- Not posted in the source record
Clinical summary
The research question as the sponsor registered it. This describes what the study plans to test, not what it found.
Exercise training in Pulmonary arterial hypertension in the setting of rehabilitation leads to an enormous improvement of functional state and haemodynamics. However the underlying mechanism is still unkown. It is assumed to be relied on Right ventricular contractile reserve, but this has never been proven with goldstandard PV-loop assessment.
Our aim is to evaluate the mechanism leading to the increase in functional state and to evaluate the impact of exercise (acute and chronic) on right ventricular performance
Detailed description
The ability of the RV to increase Ees under exercise is barely understood, and it is not known whether this is accompanied by changes in Eed. Exercise-based rehabilitation programs in PAH patients showed a marked increase in 6 Minute Walk distance and CI; the improvement was, partially higher than the improvement upon targeted PAH medication Several mechanisms may underlie such improvement, in particular a decrease in PVR, improved peripheral muscular function and improved systolic and/or diastolic RV function. To assess the latter aspect in a load-independent fashion, the investigators will perform acute exercising and exercise-based rehabilitation in PAH patients with performance of RV PV loop measurements, which has never been undertaken under this aspect in PAH patients.
Acute exercising: As "physiological response" to acute exercising, an increase in RV Ees is to be expected. However, based on clinical experience and on the surprising finding of an Ees decrease upon volume challenge in patients with low Ees/Ea values, the investigators hypothesize that orientation and extent of the Ees response to acute exercise will depend on the baseline Ees/Ea: patients with well-maintained Ees/Ea values may reveal an increase of Ees in response to acute exercise, whereas patients with RV-PA uncoupling (baseline Ees/Ea < 0.8) may show an acute heterometric adaptation with increase in volumes and decrease in Ees (negative ∆ Ees). Moreover, this study may again provide a novel "threshold of uncoupling" (Ees/Ea ratio), at which the RV response to acute exercising switches from increased to decreased contractility. The investigators will use incremental exercise tests (step or ramp protocol; handgrip protocol) with repeated hemodynamic measurements with right heart catheterization (RHC) and PV-loop catheter. The modified single beat method will be used to calculate Ees and Ea as well as Eed under exercise: the intercept on the x-axis will be predefined by Valsalva maneuver and preload reduction, and this point will be the reference for PV-loop-derived ESPVR to calculate Ees as decribed before. The study will include 42 PAH patients, who will subsequently be entered into the rehabilitation program (for power calculation see below). Similar to the volume challenge study, the hypothesis is that extent and orientation of ∆ Ees upon acute exercise are correlated with baseline Ees/Ea. Primary endpoint: ∆ Ees between baseline and maximum exercise. Secondary endpoints: time to recovery of Ees and RV-EDV after acute exercising, changes in PVR, mPAP, CI, Eed, Ea, Stroke Work, EDP, ESV, EDV and SV. Statistics: the primary endpoint will be analyzed by descriptive statistics, graphical representations with scatterplots, quantitative measures of dependence (Pearson's r or Spearman´s rho) and description of conditional distributions will be used.
Exercise-based rehabilitation - the RESERVE study: The investigators aim to conduct a single center, interventional, randomized, non-blinded, prospective study to evaluate the impact of exercise training on RV-PA- coupling. Every patient will undergo acute exercise testing during first catheterization as described above. Thereafter, patients will be randomly assigned to a control and a training group for chronic exercise in a rehabilitation program. Medication will remain unchanged during the study period. After 15 weeks, RHC and PV-loop assessment at baseline and in response to acute exercise will be repeated. During the study, patients of the control group will not receive any advice on exercise training. Rehabilitation-exercise training will consist of High Intensity Interval Training (HIIT) as described before . Retesting (baseline, response to exercise) will be performed after 15 weeks. Different examinations will be performed at the different visits. Primary endpoint will be the change in baseline Ees over the 15 weeks observation period. Secondary endpoints include the Ees response to acute exercising as well as further PV-loop, cMRI, Echo-derived and functional parameters as detailed in Table 2. Statistics: Continuous variables will be compared using repeated-measures ANOVA for differences between values at baseline and after acute and chronic exercise challenge. The comparisons of characteristics at baseline and after exercise between the two groups, as well as the comparisons of the absolute changes of variables from baseline to post-exercise between groups will be analyzed by adequate descriptive statistics.
Study design
- Primary purpose
- Treatment
- Allocation
- Randomised
- Intervention model
- Single group
- Masking
- None (open label)
- Number of arms
- 2
- Model description
- Patients will randomized for exercice (1:1). After 15 weeks the group without exercise will be offered to take part in an exercise training
| Arm | Type | Receives |
|---|---|---|
| Exercise | Other | Other: ExerciseGroup under exercise training for 15 weeks with High intenstiy interval training under medical control |
| Control | No intervention | –Group with standard care according to current guidelines |
Who may qualify
- Ages
- 18 to 75 years
- Sex
- All
- Healthy volunteers
- Not accepted
- Age groups
- Adult, Older adult
Key inclusion criteria (3 listed)
- Consent form,
- men and women> 18 years <75 years
- invasively confirmed chronic PH who have received complete diagnostic evaluation by specialized physicians according to at a center for pulmonary hypertension and were adjusted for 2 months under intensive medical therapy and are stable
Key exclusion criteria (5 listed)
- Pregnancy or lactation,
- Change in medication during the last 2 months,
- Patients with signs of right heart decompensation, severe walking disturbance,
- No previous invasively confirmation of PH, acute diseases, Infections, fever,
- active myocarditis, unstable angina pectoris, exercise-induced ventricular -arrhythmias, congestive heart failure, significant heart disease, pacemakers, and -hypertrophic obstructive cardiomyopathy, or a highly reduced left ventricular function
Eligibility is decided by the study team after screening; this overview does not establish that a patient qualifies. Full inclusion and exclusion criteria.
Interventions
| Intervention | Type | Arms |
|---|---|---|
| ExerciseHigh intensity interval training (rehabilitation) over 15 weeks. Patients will be guided by physicians for exercise training in Pulmonary hypertension | Other | Exercise |
Primary outcome
Primary endpoint will be the change in baseline Ees over the 15 weeks observation period
Time frame: over 15 weeks
Ees(endsystolic elastance) is a measure of coontractility
8 secondary outcomes
Global longitudinal strain
Time frame: over 15 weeks
PVR
Time frame: April 2020 until July 2022
Walking distance in 6MW
Time frame: over 15 weeks
TAPSE,
Time frame: over 15 weeks
mPAP
Time frame: over 15 weeks
Cardiac Output
Time frame: over 15 weeks
T1 mapping
Time frame: over 15 weeks
Fractional area change
Time frame: over 15 weeks
Results and safety
Results are not available in the source record.
Research links
- Official record on ClinicalTrials.govLast updated by the sponsor 9 Nov 2021.
- Individual participant dataSharing planned: No
Related trials for Pulmonary Hypertension
Not yet recruitingPhase 2/3
An Open-Label Extension Study to Evaluate Inhaled Treprostinil SMI in Participants With Pulmonary Hypertension Associated With Chronic Obstructive Pulmonary Disease (PH-COPD)
Pulmonary Hypertension Associated With Chronic Obstructive Pulmonary Disease
Not yet recruitingPhase 2
Study of Treprostinil Administered Via Soft Mist Inhaler (SMI) in Participants With Pulmonary Hypertension Associated With Chronic Obstructive Pulmonary Disease (PH-COPD)
Pulmonary Hypertension Associated With Chronic Obstructive Pulmonary Disease
Active, not recruitingPhase 1
A Pilot Study of Microbiota Transplant With Antibiotic Preconditioning and Fiber Supplementation in Pulmonary Arterial Hypertension (GUT RESTORE-PAH)
Pulmonary Arterial Hypertension
RecruitingObservational study
Natural History Study of Biomarkers in Pulmonary Arterial Hypertension
Pulmonary Disease, Pulmonary Hypertension
Active, not recruitingPhase 1
Study of Intravenous ZMA001 in Healthy Subjects
Pulmonary Arterial Hypertension PAH
Referral and contact
AzTrials does not enrol participants or take referrals. Contact the study team or a site listed below; they decide who can take part. This study is not recruiting at the moment.
1 site in 1 country: see every site and its status.
Questions about this trial
What is this clinical trial studying?
A study testing Exercise in people with Pulmonary Hypertension and Right Heart Failure, run by University of Giessen at 1 site in Germany.
The full registered description is in the About this study section and the official record.
Who may be eligible to take part?
The sponsor lists 3 inclusion and 5 exclusion criteria. Eligibility is decided by the study team after screening, so read the full criteria and contact a listed site.
Is this clinical trial currently recruiting?
The record says: status not confirmed, as of the sponsor's last update on 9 Nov 2021. Status can change between updates, so confirm with the study contact before making plans.
Where is the study taking place?
The record lists 1 site in Germany. Whether a site is taking part right now should be confirmed with that site. See every site.
What are the possible benefits and risks?
They depend on the study and the treatment, and no study can promise a benefit. The study team explains the known risks during informed consent, before anyone joins; the record itself does not list them.
Are results available for this study?
Results are not available in the source record.
How can a doctor refer a patient or contact the research team?
Each site lists its own contact: choose the nearest one under Trial locations. AzTrials does not enrol participants or take referrals.
What does the primary outcome measure?
Primary endpoint will be the change in baseline Ees over the 15 weeks observation period (time frame: over 15 weeks). It is what the study was designed to measure, not a finding.
Where can I read the original study information?
Does a listing mean the treatment is approved or proven to work?
No. A listing means the study is registered. It does not show that the treatment is safe, works, or is approved by a regulator.
How often is this information updated?
AzTrials copies changed records from ClinicalTrials.gov every night and reloads the whole registry every week. The sponsor last updated this record on 9 Nov 2021.